Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease

Mov Disord. 2017 Apr;32(4):530-537. doi: 10.1002/mds.26947. Epub 2017 Mar 3.

Abstract

Background: Long-term levodopa (l-dopa) treatment is associated with the development of l-dopa-induced dyskinesias in the majority of patients with Parkinson disease (PD). The etiopathogonesis and mechanisms underlying l-dopa-induced dyskinesias are not well understood.

Methods: We used striatal optogenetic stimulation to induce dyskinesias in a hemiparkinsonian model of PD in rats. Striatal dopamine depletion was induced unilaterally by 6-hydroxydopamine injection into the medial forebrain bundle. For the optogenetic manipulation, we injected adeno-associated virus particles expressing channelrhodopsin to stimulate striatal medium spiny neurons with a laser source.

Results: Simultaneous optical activation of medium spiny neurons of the direct and indirect striatal pathways in the 6-hydroxydopamine lesion but l-dopa naïve rats induced involuntary movements similar to l-dopa-induced dyskinesias, labeled here as optodyskinesias. Noticeably, optodyskinesias were facilitated by l-dopa in animals that did not respond initially to the laser stimulation. In general, optodyskinesias lasted while the laser stimulus was applied, but in some instances remained ongoing for a few seconds after the laser was off. Postmortem tissue analysis revealed increased FosB expression, a molecular marker of l-dopa-induced dyskinesias, primarily in medium spiny neurons of the direct pathway in the dopamine-depleted hemisphere.

Conclusion: Selective optogenetic activation of the dorsolateral striatum elicits dyskinesias in the 6-hydroxydopamine rat model of PD. This effect was associated with a preferential activation of the direct striato-nigral pathway. These results potentially open new avenues in the understanding of mechanisms involved in l-dopa-induced dyskinesias. © 2017 International Parkinson and Movement Disorder Society.

Keywords: Parkinson disease; dyskinesias; l-dopa; medium spiny neurons; optogenetics.

MeSH terms

  • Adrenergic Agents / toxicity*
  • Animals
  • Antiparkinson Agents / adverse effects
  • Brain / metabolism
  • Channelrhodopsins
  • Corpus Striatum / metabolism*
  • Disease Models, Animal
  • Dynorphins / metabolism
  • Dyskinesias / etiology*
  • Functional Laterality
  • Levodopa / adverse effects
  • Male
  • Optogenetics / adverse effects*
  • Oxidopamine / toxicity*
  • Parkinson Disease / etiology*
  • Parkinson Disease / pathology
  • Parkinson Disease / physiopathology
  • Proto-Oncogene Proteins c-fos / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Transduction, Genetic
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Adrenergic Agents
  • Antiparkinson Agents
  • Channelrhodopsins
  • Fosb protein, rat
  • Proto-Oncogene Proteins c-fos
  • Levodopa
  • Dynorphins
  • Oxidopamine
  • Tyrosine 3-Monooxygenase